Pilot Study of Topical Trifluridine for the Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients with AIDS (ACTG 172)

Journal of Acquired Immune Deficiency Syndromes

Volumn 12, Issue 2, 1996, Pages 147-152

  Kessler, H A ^a   Hurwitz, S ^b   Farthing, C ^c   Benson, C A ^a   Feinberg, J ^d   Kuritzkes, D R ^e   Bailey, T C ^f   Safrin, S ^g   Steigbigel, R T ^h   Cheeseman, S H ⁱ   McKinley, Hug F ^j   Wettlaufer, B ^b   Owens, S ^k   Nevin, T ^l   Korvick, J A ^l  

^a RUSH MEDICAL COLLEGE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h STONY BROOK UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MASSACHUSETTS   (United States)

^j Frontier Sci/Technol Res Found ^*  (United States)

^k FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^l NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

Acyclovir; Herpes simplex; HIV; Resistance; Topical; Trifluridine

Indexed keywords

ACICLOVIR; FOSCARNET; TRIFLURIDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HERPES SIMPLEX; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL; SCORING SYSTEM; TOPICAL DRUG ADMINISTRATION; TREATMENT FAILURE;

ACYCLOVIR; ADMINISTRATION, TOPICAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CHRONIC DISEASE; DRUG RESISTANCE, MICROBIAL; FEMALE; HERPES SIMPLEX; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SAFETY; TRIFLURIDINE;

HERPES; SIMPLEXVIRUS;

EID: 0029937485     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199606010-00007     Document Type: Article

References (34)

1. Quinnan GV, Masur H, Rook AH, et al. Herpesvirus infections in the acquired immune deficiency syndrome. JAMA 1984;252:72-7.
2. Nishimura K, Nagamoto A, Igarashi M. Extensive skin manifestations of herpesvirus infection in an acute leukemic child. Pediatrics 1972;49:294-7.
3. Muller SA, Hermann EC, Winkelmann RK. Herpes simplex infections in hematologic malignancies. Am J Med 1972;52:102-14.
4. Nahmias AJ, Roizman B. Infection with herpes-simplex viruses 1 and 2. N Engl J Med 1973;289:667-74,719-25,781-9.
5. Stone WJ, Scowden EB, Spannuth CL, Lowry SP, Alford RH. Atypical herpes simplex virus hominis type 2 infection in uremic patients receiving immunosuppressive therapy. Am J Med 1977;6:511-6.
6. Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980;142:338-46.
7. Whitley RJ, Barton N, Collins E, Whelchel J, Diethelm AG. Mucocutaneous herpes simplex virus infections in immunocompromised patients: a model for evaluation of topical antiviral agents. Am J Med 1982;73:236-40.
8. Siegal FP, Lopez C, Hammer GS, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981;305:1439-44.
9. Norris SA, Kessler HA, Fife KH. Severe, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS. J Infect Dis 1988;157:209-10.
10. Erlich KS, Jacobson MA, Koehler JE, et al. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS): an uncontrolled trial. Ann Intern Med 1989;110:710-3.
11. Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 1989;320:297-300.
12. Marks GL, Nolan PE, Erlich KS, Ellis MN. Mucocutaneous dissemination of acyclovir-resistant herpes simplex virus in a patient with AIDS. Rev Infect Dis 1989;11:474-6.
13. Engel JP, Englund JA, Fletcher CV, Hill EL. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. JAMA 1990;263:1662-4.
14. Birch CJ, Tachedjian G, Doherty RR, Hayes K, Gust ID. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J Infect Dis 1990;162:731-4.
15. Safrin S, Crumpacker CS, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325:551-5.
16. Mitchell CD, Bean B, Gentry SR, Groth KE, Boen JR, Balfour HH. Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet 1981;2:1389-92.
17. Straus SE, Smith HA, Brickman C, de Miranda P, McLaren C, Keeney RE. Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunocompromised patients. Ann Intern Med 1982;996:270-7.
18. Straus SE, Seidlin M, Takiff H, Jacobs D, Bowen D, Smith HA. Oral acyclovir to suppress recurring herpes simplex virus infections in immunodeficient patients. Ann Intern Med 1984;100:522-4.
19. Gnann J, Whitley RJ. Acyclovir: a decade later. N Engl J Med 1992;327:782-9.
20. Fletcher CV, Englund JA, Bean B, Chinnock B, Brundage DM, Balfour HH. Continuous infusion of high dose acyclovir for serious herpesvirus infections. Antimicrob Agents Chemother 1989;33:1375-8.
21. Hill EL, Hunter GA, Ellis MN. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1991;35:2322-8.
22. Safrin S, Elbeik T, Phan L, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1994;38:1246-50.
23. Balfour HH. Resistance of herpes simplex to acyclovir. Ann Intern Med 1983;98:404-6.
24. Field H, Darby G, Wildy P. Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus. J Gen Virol 1980;49:115-24.
25. Darby G, Field HJ. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature 1981;289:81-3.
26. Ellis MM, Keller DM, Fyfe JL, et al. Clinical isolate of herpes simplex type 2 that induces a thymidine kinase with altered substrate specificity. Antimicrob Agents Chemother 1987;31:1117-25.
27. Sacks S, Wanklin RJ, Reece D, Hicks KA, Tyler KL, Coen DM. Progressive esophagitis from acyclovir-resistant herpes simplex. Ann intern Med 1989;111:893-9.
28. Safrin S, Assaykeen T, Follansbee SE, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 1990;161:1078-84.
29. Weaver D, Weissbach N, Kapell K, Benson CA, Pottage JC, Kessler HA. Topical trifluridine (Trifluridine) treatment of acyclovir-resistant (ACV-R) herpes simplex disease [Abstract 507]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology. 1991.
30. Birch CJ, Tyssen DP, Tachedjian G, et al. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. J Infect Dis 1992;166:108-12.
31. Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections. Drug Eval 1982;23:329-53.
32. Whitley RJ, Levin M, Barton N, et al. Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy. J Infect Dis 1989;150:323-9.
33. Pottage JC, Kessler HA. Herpes simplex virus resistance to acyclovir: clinical relevance. Infect Agents Dis 1995;4:115-24.
34. Spruance SL, McKeough M, Sugibayashi K, Robertson F, Gaede P, Clark DS. Effect of azone and propylene glycol on penetration of trifluorothymidine through skin and efficacy of different topical formulations against cutaneous herpes simplex virus infections in guinea pigs. Antimicrob Agents Chemother 1984;26:819-23.